GV20-0251
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for GV20-0251, covering 2025-02-13 to 2026-03-25. Get the full timeline:
Most recent: Clinical Trial Update: GV20-0251 and Sintilimab for Neoadjuvant Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Study [Phase 1]